What is the target of Sorafenib?

Sorafenibis an oralTKI that works by blocking vascular endothelial growth factor receptors(VEGFR)1–3, platelet-derived growth factor receptor(PDGFR) beta- pathway and Raf-MEK-ERK signaling, targeting the angiogenesis and proliferation pathways of tumors.

Sorafenib is a diaryl urea and oral multikinase inhibitor that targets cell surface tyrosine kinase receptors and downstream intracellular kinases involved in tumor cell proliferation and tumor angiogenesis. The FDAand the European Commission first approved sorafenib for the treatment of hepatocellular carcinoma in 2007. Sorafenib is also used to treat renal cancer and differentiated thyroid cancer.

Sorafenib undergoes oxidative metabolism in the liver via CYP3A4 and glucuronidation in the liver and kidney via UGT1A9. At steady state, sorafenib accounts for 70-85% of circulating analytes in plasma. Approximately eight metabolites of sorafenib have been identified, five of which were detected in plasma. The major circulating metabolite is the pyridine N-oxide form, which accounts for approximately 9–16 % of the total steady-state circulating dose: the pharmacological activity of this metabolite is comparable to that of the parent drug. Oral100 After mg doses of sorafenib, approximately 96% of doses were recovered within 14 days, with the rest 77% of the dose is excreted in the feces, and 19% of the dose is excreted in the urine as glucuronidated metabolites. Unaltered sorafenib accounted for 51% of the fecal excreted dose. The retail price of Bangladesh Yaopin International Pharmaceutical 0.2g*120 tablets is about 700 yuan. The retail price of pharmaceuticals in Laos and ASEAN is about 0.2g*56 tablets500yuan. IndiaNATCOPharmaceutical retail price0.2g*120tablets1000yuan. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.